RxDoctor Payments Data

Danyelle Simmons

Psychiatric/Mental Health · Salem, ORNPI 1184336893

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,000in general payments, 2019–2025

Across 180 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$464
  • Otsuka America Pharmaceutical, Inc.$434
  • AbbVie$367
  • Lundbeck LLC$316
  • Teva Pharmaceuticals USA, Inc.$255
  • Almatica Pharma LLC$229
  • plus $936 from 15 others

What the payments were for

  • Food & beverage$2,83494%
  • Education$1666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,000 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

See all psychiatric/mental health providers in Oregon

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole14$23,537
VraylarCariprazine Hcl14$19,588
CaplytaLumateperone Tosylate11$18,012
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine30$1,304
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$750
Hydroxyzine Hcl53$510
Lamotrigine51$418
Buspirone Hcl54$380
Sertraline Hcl22$308
Oxcarbazepine11$295
Mirtazapine13$260
Prazosin Hcl21$215
Aripiprazole23$199
Duloxetine Hcl24$196
Bupropion XlBupropion Hcl19$183

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$434$23,53714 claims
AbbVieVraylar$367$19,58814 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$464$18,01211 claims
Almatica Pharma LLCSertraline Hcl$229$30822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 540 psychiatric/mental health providers in Oregon.

Other psychiatric/mental health in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →